A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that down-regulates hepatic low-density lipoprotein receptor (LDLR) by binding and shuttling LDLR to lysosomes for degradation. The development of therapy that inhibits PCSK9 has attracted considerable attention...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xuelei, Chen, Xiaofang, Zhang, Xiumin, Su, Chunyan, Yang, Mengxia, He, Wei, Du, Yu, Si, Shuyi, Wang, Li, Hong, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026728/
https://www.ncbi.nlm.nih.gov/pubmed/32058941
http://dx.doi.org/10.1016/j.ebiom.2020.102650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026728/
https://www.ncbi.nlm.nih.gov/pubmed/32058941
http://dx.doi.org/10.1016/j.ebiom.2020.102650

Ejemplares similares